Free Forum – RESPONDING TO TRUMP Eddie Kurtz, Courage Campaign – Colby Devitt, Standing Rock First NEW SHOW since 2014. Opens w 15 minute commentary.

Written on January 14th, 2017

After hosting and producing this show for 17 years, I stepped away from recording new live interviews nearly two years ago, but I couldn’t resist commenting about Trump’s election and our path forward confronting his administration. The Courage Campaign is spearheading resistance in California with a mix of online and ground organizing and action. Colby Devitt shares her experience at Standing Rock and her work in the campaign to divest from banks funding the pipeline.

Disruptive #5: Molecular Robotics – Building with DNA

Written on April 5th, 2016

unnamed

DISRUPTIVE – the podcast from Harvard’s Wyss Institute for Biologically Inspired Engineering.

We’re learning to take advantage of properties of DNA that have served nature well- but in ways nature may have never pursued. We build with it. We tap its capacity to carry information to enhance our ability to explore the inner life of cells.

In this episode, Wyss faculty members William Shih, Wesley Wong and Peng Yin share what it’s like being on the frontier of science, explain how and why they program DNA, and consider potential applications of their work.

http://wyss.harvard.edu

Disruptive: Molecular Robotics transcript

Tap the Unique Power of Story and Narrative

Written on February 23rd, 2016

 

 


 

 
 
In this podcast, I go solo. Rather than interviewing others, I share with you the best of the work I do to help organizations develop more engaging narratives and tell better stories. Learn why narrative is uniquely powerful as well as the recipe for a good story – whether in a Hollywood screenplay or a one-to-one conversation. 

Disruptive: Synthetic Biology Pamela Silver & George Church

Written on February 21st, 2016

disruptive

 

 

 

I’m excited to offer the first episode of DISRUPTIVE, my new monthly podcast series produced with Harvard’s Wyss Institute for Biologically Inspired Engineering. The mission of the Wyss Institute is to: Transform healthcare, industry, and the environment by emulating the way nature builds, with a focus on technology development and its translation into products and therapies that will have an impact on the world in which we live. Their work is disruptive not only in terms of science but also in how they stretch the usual boundaries of academia.

In this inaugural episode, Wyss core faculty members Pamela Silver and George Church explain how, with today’s technology breakthroughs, modifications to an organism’s genome can be conducted more cheaply, efficiently, and effectively than ever before. Researchers are programming microbes to treat wastewater, generate electricity, manufacture jet fuel, create hemoglobin, and fabricate new drugs. What sounds like science fiction to most of us might be a reality in our lifetimes: the ability to build diagnostic tools that live within our bodies, find ways to eradicate malaria from mosquito lines, or possibly even make genetic improvements in humans that are passed down to future generations. Silver and Church discuss both the high-impact benefits of their work as well as their commitment to the prevention of unintended consequences in this new age of genetic engineering.

http://wyss.harvard.edu/

 

Disruptive: Cancer Vaccine & Hydrogel Drug Delivery

Written on December 5th, 2015

Disruptive#4-vert

Welcome to DISRUPTIVE the podcast from Harvard’s Wyss Institute for Biologically Inspired Engineering.

In this episode of DISRUPTIVE, we will focus on a cancer vaccine and hydrogel drug depots – both being developed by Wyss Founding Core Faculty Member, DAVE MOONEY. Mooney says the human immune system is the most efficient weapon on the planet to fight disease. Cancer, however, resists treatment and cure by evading the immune system. Unlike bacterial cells or viruses, cancer cells belong in the body, but are simply mutated and misplaced. Scientists have been trying to develop vaccines that provoke the immune system to recognize cancer cells as foreign and attack them. The approach developed by Mooney’s group, in which they reprogram immune cells from inside the body using implantable biomaterials, appears simpler and more effective than other cancer vaccines currently in clinical trials. In one study, 50% of mice treated with two doses of the vaccine — mice that would have otherwise died from melanoma within about 25 days — showed complete tumor regression. On a second front, when it comes to delivering drugs or protein-based therapeutics, doctors often give patients pills or inject the drug into their bloodstream. Both are inefficient methods for delivering effective doses to targeted tissues. Mooney and his team at Wyss are taking a new approach using biocompatible and biodegradable hydrogels. They’ve developed a gel-based sponge that can be molded to any shape, loaded with drugs or stem cells, compressed to a fraction of its size, and delivered via injection. Once inside the body, it pops back to its original shape, gradually releases its payload, and safely degrades. After we explore both of these exciting projects with Mooney, we take a closer look at the process of translation of hydrogel technology into products and therapies with Chris Gemmiti, a business development lead at Wyss.

http://wyss.harvard.edu